Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients Financial Results: Divis Laboratories Ltd reported Revenues for
Divi's Laboratories Ltd
-(DIVISLAB)
XNSE:DIVISLAB, XBOM:DIVISLAB
DIVISLAB Q3 2024-2025 Call Highlights: Expansion Plans, Generics Growth, and API Challenges!
Divi's Laboratories Ltd., an Indian multinational pharmaceutical company that manufactures and exports API's, Intermediates and Nutraceutical ingredients, in its Q3 earnings call
Divis Laboratories Ltd Q2FY25; 47% rise in Profits
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients Financial Results: Divis Laboratories Ltd reported Revenues for
Divis Laboratories Ltd Q1FY25; 21% rise in Profits
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients Financial Results: Divis Laboratories Ltd reported Revenues for
Divi’s Laboratories Ltd Q4FY24; 68% rise in Profits
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients Financial Results: Divi's Laboratories Ltd reported Revenues for
Divi’s Laboratories Ltd Q3FY24; 17% rise in Profits
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients Financial Results: Divi's Laboratories Ltd reported Revenues for
Divi’s Laboratories Ltd Q3 FY24 Earnings Conference Call Insights
Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q3 FY24 Earnings Concall Growth and Performance Witnessed a steady 3Q driven by expanding market
Divis Laboratories Ltd Q2FY24; 29% fall in Profits
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients Financial Results: Divis Laboratories Ltd reported Revenues for
Divi’s Laboratories Ltd Q2 FY24 Earnings Conference Call Insights
Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q2 FY24 Earnings Concall Business Overview Anticipating growth opportunities in contrast media, sartans, soon-to-expire patented
Divi’s Laboratories: Pioneering Innovation and Growth in the Pharmaceutical Frontier
Stock Data: TickerNSE: DIVISLABSExchangeNSEIndustryPharmaceutical Price Performance: Last 5 Days+0.43 %YTD+12.23 %Last 12 Months+5.91 %As on 20-09-2023 Company Description: Divi's Laboratories is a
Divi’s Laboratories Ltd Q1FY24; 49% fall in Profits
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients Financial Results: Divi's Laboratories Ltd reported Revenues for
Earnings | Divis Laboratories Ltd (NSE: DIVISLAB): Q4FY23 Results Out; Total Income fell 21% YoY.
Divis Laboratories Ltd is a renowned Indian company specializing in the production and global export of Active Pharmaceutical Ingredients (APIs), Intermediates, and
Divi’s Laboratories Ltd Q4 FY23 Earnings Conference Call Insights
Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:11:30] Tushar Manudhane from Motilal Oswal asked if backward
Divi’s Laboratories Limited Q4 FY23; Net Profit Down By 64%
Divi's Laboratories Limited reported Total Income for Q4 FY23 of ₹2,016.92 Crore down from ₹2,570.83 Crore year on year, a decline of
Divi’s Laboratories Ltd (DIVISLAB) Q4 FY23 Earnings Concall Transcript
Divi's Laboratories Ltd (NSE: DIVISLAB) Q4 FY23 Earnings Concall dated May. 20, 2023 Corporate Participants: M. Satish Choudhury -- Company Secretary and Chief Investor
Divi’s Laboratories Ltd (DIVISLAB) Q3 FY23 Earnings Concall Transcript
Divi's Laboratories Ltd (NSE: DIVISLAB) Q3 FY23 Earnings Concall dated Feb. 03, 2023 Corporate Participants: M. Satish Choudhury -- Company Secretary and Chief Investor
Divis Labs Ltd.(NSE:DIVISLAB )|Q3 FY23 Results Out|Total Income rises 5% yoy
Divi's Laboratories Limited (NSE: DIVISLAB) is a pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs) and intermediates. The company
Divi’s Laboratories Ltd Q2 FY23 Earnings Conference Call Insights
https://youtu.be/e1-tljnhSVM Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q2 FY23 Earnings Concall Management Update: [00:06:48] DIVISLAB stated that though global logistics scenario
Divi’s Laboratories Q2FY23; 19% Fall in Profits
Divi's Laboratories Ltd.'s revenues in Q2FY23 fell 7% to ₹ 1,855 crores. Consolidated Profit came at ₹ 494 crores showcasing a 19%
Divi’s Laboratories Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/EPaxfKgyoZQ Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Q&A Highlights: Tushar Manudhane from Motilal Oswal asked about the
Divi’s Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Transcript
Divi's Laboratories Ltd (NSE:DIVISLAB) Q1 FY23 Earnings Concall dated Aug. 12, 2022 Corporate Participants: Satish Choudhury -- Company Secretary and Chief Investor